Abstract
Hepatocellular carcinoma (HCC) is a leading cause of cancer related death both in the United States and worldwide. Proper management begins with identification of high risk individuals who may benefit from a screening program for HCC, since early detection of this cancer can lead to improved survival. Advances in radiographic technology and new staging systems that take tumor burden and clinical status into account allow patients to be more accurately stratified into proper treatment groups. Depending on the cancer stage, treatments such as radiofrequency ablation (RFA), surgical resection and liver transplantation offer a potential cure, while other treatments such as transarterial chemoembolization (TACE) can prolong life with HCC. New agents such as the oral multikinase inhibitor sorafenib show promise of slowing disease through utilization of molecular targeting. In this article, we will review management strategies of HCC, from diagnosis to treatment.
Keywords: Hepatocellular carcinoma, therapy, liver transplantation, diagnosis
Current Cancer Therapy Reviews
Title: Current Treatment Strategies for Hepatocellular Carcinoma
Volume: 6 Issue: 3
Author(s): Andrew Aronsohn and Smruti R. Mohanty
Affiliation:
Keywords: Hepatocellular carcinoma, therapy, liver transplantation, diagnosis
Abstract: Hepatocellular carcinoma (HCC) is a leading cause of cancer related death both in the United States and worldwide. Proper management begins with identification of high risk individuals who may benefit from a screening program for HCC, since early detection of this cancer can lead to improved survival. Advances in radiographic technology and new staging systems that take tumor burden and clinical status into account allow patients to be more accurately stratified into proper treatment groups. Depending on the cancer stage, treatments such as radiofrequency ablation (RFA), surgical resection and liver transplantation offer a potential cure, while other treatments such as transarterial chemoembolization (TACE) can prolong life with HCC. New agents such as the oral multikinase inhibitor sorafenib show promise of slowing disease through utilization of molecular targeting. In this article, we will review management strategies of HCC, from diagnosis to treatment.
Export Options
About this article
Cite this article as:
Aronsohn Andrew and R. Mohanty Smruti, Current Treatment Strategies for Hepatocellular Carcinoma, Current Cancer Therapy Reviews 2010; 6 (3) . https://dx.doi.org/10.2174/157339410791698151
DOI https://dx.doi.org/10.2174/157339410791698151 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The anti-inflammatory agents Siblings Nitroxyl (HNO) and Nitric Oxide (NO) in Cardioprotection
Drug Design Reviews - Online (Discontinued) Assessing Systemic Arterial Hypertension Through Echocardiography: A Review for the Clinician
Current Hypertension Reviews Desmoteplase for Acute Ischemic Stroke: A Systematic Review and Metaanalysis of Randomized Controlled Trials
CNS & Neurological Disorders - Drug Targets New Insights in Mast Cell Modulation by Palmitoylethanolamide
CNS & Neurological Disorders - Drug Targets ACE Inhibitors and ARBs for Obesity-Related Hypertension
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Cognitive Decline as a Consequence of Essential Hypertension
Current Pharmaceutical Design Molecular Mechanisms Involved in the Control of Neurohypophyseal Hormones Secretion
Current Pharmaceutical Design Pancreastatin, A Regulatory Peptide that Modulates Energy Metabolism
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Purine Ionotropic (P2X) Receptors
Current Pharmaceutical Design Automated Electrophysiology in Drug Discovery
Current Pharmaceutical Design The Role of Selectins During Lung Inflammation and Their Potential Impact for Innovative Therapeutic Strategies
Current Respiratory Medicine Reviews The Concomitance of Hypertension and Diabetes Exacerbating Retinopathy: The Role of Inflammation and Oxidative Stress.
Current Clinical Pharmacology Diabetes-induced Epigenetic Signature in Vascular Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Cardiovascular Disease and Inflammation: Novel Biomarkers of Inflammation and Endothelial Activation
Vascular Disease Prevention (Discontinued) Aquaporins as Targets for Drug Discovery
Current Pharmaceutical Design Editorial[Hot Topic:Membrane Channels as Therapeutic Targets (Executive Editor: Jean-Claude Herve)]
Current Pharmaceutical Design A Single Pill to Treat Postmenopausal Hypertension? Not Yet
Current Topics in Medicinal Chemistry Cardiovascular Benefits of Extended-Time Nocturnal Hemodialysis
Current Vascular Pharmacology Anti-miRNA-23a Oligonucleotide Suppresses Glioma Cells Growth by Targeting Apoptotic Protease Activating Factor-1
Current Pharmaceutical Design A Case of Ischemic Stroke in Acute Promyelocytic Leukemia at Initial Presentation: Relevance of All-Trans Retinoic Acid Treatment
Cardiovascular & Hematological Disorders-Drug Targets